肥満と減量療法のジャーナル

抽象的な

8-Weeks of β-GPA Treatment Reduces Body Mass While Positively Altering Translation Initiation in Obese Skeletal Muscle

Joshua C. Drake, Lauryn Benninger and David L. Williamson

The aim of this study was to determine how 3-guanidinopropionic acid (?-GPA) treatment, that reduces body mass, alters obese skeletal muscle mass and regulatory mechanisms controlling muscle mass. Lean (L) and ob/ ob (O) mice were fed either a control (C) or a ?-GPA-containing (F) diet for 8 weeks. Body mass decreased in both ?-GPA treated groups. Despite a lower plantar flexor-complex muscle mass, both ?-GPA treated groups achieved the same muscle mass. Raptor-mammalian Target of Rapamycin protein association was lower in OC muscle (vs. LC) and was not altered with ?-GPA, despite reductions in S6K1 activation (OF only). 4E-BP1 phosphorylation increased in the ?-GPA treated groups, but only the OF mice displayed an increase in eIF4E phosphorylation that corresponded with a trending increase in eIF4G-eIF4E association. Thus, long-term ?-GPA treatment augments obesity-induced dysregulation of mechanisms controlling skeletal muscle mass to that of the lean, while reducing body mass.